Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The castration-resistant prostate cancer CRPC or hormone-refractory prostate cancer HRPCA therapeutics market has exhibited ...

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Global Sepsis Treatment Market Report: Growth, Expansion, and Strategic Insights (2025–2033) The Global Sepsis Treat ...

Of course, some of the rally’s nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in ...

Bristol-Myers Squibb announced promising progress on its Phase 2 Alzheimer’s clinical trial of BMS-986446, an experimental ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...